

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Platelet derived growth factor receptor B (PDGFRB; PDGFRI; CD140B)	<p>Mouse studies suggest thalidomide could help reduce cardiotoxicity in patients with cancer given Sutent sunitinib. In mice, sunitinib induced cardiotoxicity and microvascular dysfunction. In mice with transverse aortic constriction, sunitinib decreased Pdgfrb expression and pericyte numbers in the microvasculature compared with no treatment. In the same mice, thalidomide decreased sunitinib-induced cardiotoxicity compared with vehicle. Next steps include exploring low-dose thalidomide in combination with various PDGFR inhibitors and understanding the role of pericytes in the heart. Pfizer Inc. markets the receptor tyrosine kinase (RTK) inhibitor Sutent to treat gastrointestinal stromal tumors (GISTs) and advanced renal cell carcinoma (RCC). Celgene Corp. markets thalidomide as Thalomid.</p> <p><b>SciBX 6(25); doi:10.1038/scibx.2013.621</b>  <b>Published online June 27, 2013</b></p>	Patent and licensing status undisclosed	<p>Chintalgattu, V. <i>et al. Sci. Transl. Med.</i>; published online May 29, 2013; doi:10.1126/scitranslmed.3005066  <b>Contact:</b> Aarif Y. Khakoo, Amgen Inc., South San Francisco, Calif.                      e-mail: <a href="mailto:akhakoo@amgen.com">akhakoo@amgen.com</a>  <b>Contact:</b> Vishnu Chintalgattu, same affiliation as above                      e-mail: <a href="mailto:vishnuc@amgen.com">vishnuc@amgen.com</a></p>